VRDN Q2 2017 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$2B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$718,000-17.8% YoY

Gross Profit

-$5M-664.2% margin

Operating Income

-$7M-1023.7% margin

Net Income

-$7M-1018.4% margin

EPS (Diluted)

$-5.12

QoQ Revenue Growth

+55.4%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$595,000

Balance Sheet

Total Assets

$50M

Total Liabilities

$9M

Stockholders' Equity

$41M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$718,000	$874,000	-17.8%
Gross Profit	-$5M	$246,000	-2038.6%
Operating Income	-$7M	-$2M	-195.9%
Net Income	-$7M	-$3M	-191.7%